Table 2.

Studies on NAC response with IHC- or RNA-panel subtyping.

Study	n, NAC	Regimen	k, Subtypes and Classifier	Response Criteria	Response	Survival Post-NAC
Baras et al. [48]	33 + 37	≥2 GC	2, (inferred Lum, Ba/Sq)	Tumor reduction, ≤pT1	↑Lum, ↓Ba/Sq	Not reported
Zhang et al. abstract [49]	99	≥2 GC	2, (Lum, Basal)	pCR pT0N0, pPR < pT2N0	pCR N.S. pPR ↑Lum ↓Basal	↑NAC benefit Lum
Font et al. [50]	126	GC CMV GCa	3, (Lum, BASQ, mixed)	pT0N0	↑BASQ ↓Lum ↓Mixed	N.S.
Sjödahl et al. [36]	125	≥2 MVAC GC	5, LundTax	pT0N0	↑GU ↓Ba/Sq	↑GU, Uro ↓Ba/Sq
Pichler et al. [51]	21	GC	2, (inferred Lum, Basal)	≤pT1N0	pR in 2 basal/DN, and in 57% of Lum	Not reported
Morselli et al. [52]	16	3 GC	2, (inferred Lum, Basal)	≤pT1N0	All 5 pR in Lum. 0/5 in Basal	N.S.
Jütte et al. [53]	54	2–3 GC	2, (inferred Lum, Basal)	pT0N0	↑Lum	Not reported
Razzaghdoust et al. [54]	63	GC GCa	4, (Lum, Basal, DN, DP)	Clinical (cystoscopy, CT)	↑Basal ↓DP, DN.	N.S.

Abbreviations: NAC, neoadjuvant chemotherapy; GC, gemcitabine and cisplatin; CMV, cisplatin metotrexate and vinblastine; GCa, gemcitabline and carboplatin; MVAC, metotrexate vinblastine adriamycin and cisplatin; Lum, luminal; Ba/Sq, basal/squamous; BASQ, basal squamous-like; LundTax, Lund taxonomy; DN, double negative; DP, double positive; pT, pathologic T-stage; pCR, Pathologic complete response; pPR, pathologic partial response; CT, computerized tomography; N.S., not significant; GU, genomically unstable; pR, pathologic response.